Introduction
The mammalian kidney is a complex organ composed of more than 20 different cell types. 1 Remarkably, most cells found in the adult kidney are derived from only 2 primordial tissues: an initial epithelial structure called the ureteric bud and the surrounding cap of nephron progenitor cells originating from the metanephric mesenchyme. 2 Nephron progenitor cells undergo a complex balance of self-renewal and differentiation throughout kidney development to give rise to the mature nephron. 3 Progenitor cell proliferation is a tightly regulated and crucial process throughout kidney development and represents a major phenotypic constituent of nephrogenesis in vivo. 4 Defects in nephrogenesis and ureteric branching result in congenital anomalies of the kidney and urinary tract (CAKUT). [5] [6] [7] With an incidence of 1:400, CAKUT represent one of the most frequent birth defects in humans and remain the major cause of childhood renal failure. 8 These pleiotropic malformations comprise a multitude of renal phenotypes including renal agenesis, hypoplasia, and renal dysplasia, associated with obstructive or reflexive anomalies of the ureter. A hallmark feature of CAKUT is a reduced nephron number. 9 Total nephron number, termed nephron endowment, can vary greatly even within the normal distribution, ranging from 200 000 to 1.8 million in humans. 10 Low nephron endowment within this normal range, though asymptomatic early in life, is associated with adult-onset hypertension, coronary heart diseases, and renal failure. [11] [12] [13] [14] Despite the importance of nephron endowment to human health and disease, much remains to be learned about the molecular mechanisms governing nephrogenesis.
In Situ Detection of Cell Proliferation in the Developing Kidney
Cell proliferation in nephron progenitor and ureteric bud cells during renal development is a foundational component of nephrogenesis. The ability to accurately quantify and assess in situ cellular proliferation in these lineages is crucial to increasing our knowledge of renal organogenesis. Numerous methods exist for identifying proliferating cells in situ and are broadly subdivided into DNA synthesis assays and endogenous proliferation marker assays (Table 1) .
DNA growth is an active and continuous process ( Figure  1 ), coordinating the phases of the cell cycle: G 1 (cell growth and organelle duplication), S (DNA synthesis), G 2 (further cell growth and preparation for cell division), and M (mitosis) phases. 31 Synthesis of new DNA occurs only in the S phase of the cell cycle. For the purpose of this study, we have strictly defined proliferation as the ratio of DNA-synthesizing cells to total cell population (also known as the proliferation index). Accordingly, we have restricted our analysis to S phase DNA synthesis markers 5-bromo-2'-deoxyuridine (BrdU), proliferating cell nuclear antigen (PCNA), and 5-ethynyl-2'-deoxyuridine (EdU). Notwithstanding, selection of other markers of the cell cycle may be more appropriate, dependent on specific study goals. For example, the use of phosphohistone H3 which marks M phase may be particularly helpful in tumor diagnostics, where there can be an increase in mitotic figures (Table 1 ). Late in G 1 , a control point allows the cell to commit to DNA synthesis and division, or otherwise exit the cell cycle and enter a quiescent state. 32 In addition, there is a G 2 control point which prevents damaged cells from entering mitosis. 33 Alternate measures of cell proliferation that more broadly label cellular metabolic activity (ie, labeling cells in G 1 , S, G 2 , and M phase) are more likely to overestimate actual numbers of proliferating cells due to these control points.
BrDU. Historically, the BrDU protocol has been regarded as a gold standard for in situ cell proliferation quantification in embryonic kidneys and in other developing organ systems. This protocol involves incorporation of the thymidine analogue BrDU into newly synthesized DNA (Figure 2 ), followed by detection of proliferating, BrDU-positive cells using anti-BrdU antibodies. BrDU protocols may be performed using either acid or enzymatic antigen retrieval steps. However, in order to permit access of anti-BrDU antibodies to genomic DNA, tissue sections are typically subjected to multiple denaturing conditions including incubation in acidic solutions at elevated temperatures, as well as treatment with nucleases and proteases. Ideally, co-staining would be performed to permit quantification of lineagespecific cell proliferation in nephron progenitor and ureteric bud cells.
In practice, however, the harsh experimental conditions traditionally associated with the BrDU protocol have made co-staining technically prohibitive to perform reproducibly well for several reasons. Because BrDU is a nucleotide analogue, the addition of the DNase step is necessary to unwind DNA so that the antibody can access DNA-incorporated BrdU. When working with paraffin-embedded, paraformaldehyde-or formalin-fixed sections, an additional acid antigen retrieval step is also required to consistently obtain robust BrDU staining. Not surprisingly, the multiple antigen retrieval steps required for BrDU unmasking can partially denature or destroy less stable epitopes, impairing efforts to co-stain for additional antigens of interest. Other reported difficulties associated with co-staining include incompatibility of certain antibodies with the BrDU fixation methods or with BrDU buffers, as well as antibody cross-reactivity. 34 Consequently, nephron progenitor and ureteric bud cell populations are typically identified by tissue histology following BrDU staining. Alternatively, ureteric bud cells may be identified using Dolichos biflorus agglutinin lectin staining; however, this method can be problematic due to high signal background, and inefficient labeling of ureteric bud tips. 35 A common alternative to co-labeling cell lineages in conjunction with BrDU labeling is to calculate the proliferation index, which represents cycling cells as a fraction of total tissue section area. [36] [37] [38] [39] [40] [41] [42] [43] EdU. More recently, EdU has been introduced as another thymidine analogue that is incorporated into actively dividing cells (Figure 2 ). Like BrDU, EdU can be injected intraperitoneally into laboratory animals or can be added to cell culture media. 7, 22 In contrast to BrDU, however, EdU is not detected by antibodies, but by an azide-alkyne cycloaddition "click" reaction ( Figure 3) . Briefly, each EdU molecule contains an alkyne group which, when catalyzed by copper, binds to a fluorophore-conjugated azide. 23 Importantly, the unique click chemistry developed for EdU detection effectively circumvents the necessity of tissue denaturation for antigen retrieval, rendering this protocol far more compatible with tissue co-staining for nephron progenitor and ureteric bud cells.
Bound PCNA. Proliferating cell nuclear antigen (PCNA) is a ubiquitous non-histone nuclear protein exhibiting two distinct patterns of nuclear expression depending on cell cycle, distinguishable by immunostaining methods that do not employ alcohol fixation. 19 "Free" PCNA, visualized as diffuse nuclear staining, is expressed in all cells irrespective of cell cycle phase, and functions in DNA repair and RNA transcription. 20 In contrast, "bound" PCNA is a component of the DNA replication complex and is visualized by a punctate nuclear expression pattern only in S phase cells, when bound to DNA polymerase δ and DNA polymerase ε 21 ( Figure 4 ). Here we present protocol methods for in situ detection of cell proliferation in the developing mouse kidney of BrDU, EdU, and bound PCNA. Importantly, all 3 protocols have been optimized to permit co-staining for nephron progenitors and ureteric bud cells, with anti-Six2 and anti-E Cadherin antibodies, respectively. The advantages and disadvantages of each method are discussed and must be evaluated within the specific context of the individual researcher's work when determining which method to use. Cofactor for DNA polymerase δ and ε. Expression of PCNA peaks during S phase, but is also present in G 1 and G 2 /M. 22 Detection by anti-PCNA antibodies.
Can distinguish S phase cells from other phases through identification of bound PCNA punctate staining pattern Does not require DNA denaturation or harsh tissue treatments Due to its presence in both S and non-S phase cells, increased potential for type I error (false positive) due to potentially incorrect identification of cells 22 May also detect DNA repair in addition to proliferation, increasing counts High background signal due to cytosolic staining can occur with formaldehyde fixation 19 May be residual expression in cells that have just left S phase resulting in higher type I error 19 Topoisomerase IIB An enzyme involved in uncoiling DNA for replication. Detection through antitopoisomerase IIB antibodies.
Endogenous antigen detection does not require DNA denaturation or harsh tissue treatments Found to be associated not only with replication, 23 but interact with chromosomes functionally 24, 25 and structurally 26, 27 in ways that are not fully understood: not a true measure of proliferation Phosphohistone H3
One of 5 histones that are major components of eukaryotic chromosome, present in highest concentration during M phase. 28 Detection through anti-phosphohistone H3 antibodies.
Due to its peak in M phase, this method is particularly useful in tumor diagnostics and is used as an alternative to mitotic figure counting 29 Detecting M phase is helpful in tumor diagnostics where there can be an increase in mitotic figures, but in proliferation studies mitotic figures do not accurately represent proliferating cells.
CDKs 30
There are several CDKs which are necessary for progression from one cell cycle phase to another: Cdk3 and cyclin C for G 0 phase Cdks 4, 2, and 6 and cyclins D and E for G1 phase Cdk2 and cyclins A and E for S phase Cdk2, 1, and cyclin A for G 2 Note. BrdU = 5-bromo-2'-deoxyuridine; EdU = 5-ethynyl-2'-deoxyuridine; PCNA = proliferating cell nuclear antigen; CDKs = cyclin-dependent-kinases. Co-staining for cell specific expression in addition to BrdU staining has traditionally been difficult due to the harsh treatment of tissues that destroys epitopes.
Methods
All animal experiments were carried out in accordance with the policies of the Animal Care Committee at the University of Prince Edward Island and the Canadian Council on Animal Care guidelines. CD1 dams and sires were purchased from Charles River Laboratories.
Timed Embryos
Place one or two 7-week-old CD1 dams into a sire's cage overnight. Check for vaginal plugs early the next morning and separate the dams back in to their own cages. Record gestational age of the embryos as embryonic day (E)0.5 when vaginal plug is present.
Tissue Labeling, Collection, and Processing facilitates locating embryonic kidneys which may shrink and turn translucent following tissue processing. 5. Incubate kidneys in fresh 4% PFA for a minimum of 1 hour at room temperature, or preferably overnight at 4°C. 5a. NOTE-Embryonic kidneys may become brittle following overfixation, leading to tissue fragility during embedding and sectioning. Overfixation may also lead to fixation artifacts, and antigen masking associated with loss of staining signal. 6. Dehydrate, clear, and infiltrate the tissues with paraffin wax to prepare them for embedding. This step may be performed by hand, but preferably with an automated tissue processor to maximize wax infiltration into tissue. 6a. NOTE-The following schedule was used for processing embryonic kidneys: Fresh 4% PFA or formalin 1 hour, 70% ethanol-1 hour, 70% ethanol-1 hour, 95% ethanol-1 hour, 95% ethanol-1 hour, 95% ethanol-1 hour, 100% ethanol-1 hour, 100% ethanol-1 hour clearing solution (eg, xylenes or Clear Rite) 2 × 1.5 hours, 4 changes of fresh paraffin at 60°C for 0.5 hour each. 7. Embed kidneys in paraffin wax blocks oriented to make sagittal sections, labeling each sample. Blocks may be stored indefinitely at room temperature until they are ready to be sectioned.
Tissue Sectioning
1. Trim down the blocks on the microtome until the kidney tissue becomes visible. 1a. NOTE-Early embryonic kidneys may shrink significantly and turn translucent after paraffinization; Note. EdU is incorporated into newly synthesized DNA. Cycloaddition of a fluorophore-tagged azide to the alkyne on the EdU molecule is catalyzed by the presence of copper(I). EdU = 5-ethynyl-2'-deoxyuridine.
care must be taken to avoid trimming through valuable tissue. 2. Place the trimmed wax blocks cut side down in a shallow ice water bath for 30 minutes prior to sectioning. This step increases fluidity of tissue sectioning and substantively enhances overall section quality. 
Labeling of Sections
Each of the proliferation markers is co-labeled with Six2, a marker of nephron progenitor cells, and E-cadherin (E-cad), a marker of the epithelialized ureteric bud. All antibodies are incubated on the slides in a humidified incubation chamber. Summary of antibodies used can be found in Table 2 . 
Labeling with BrdU
NOTE-Slides must be incubated first with BrDU antibodies in BrDU incubation buffer (supplied with kit) followed by a wash prior to incubation with Six2 and E-Cadherin antibodies. The increased number of washes between incubations steps results in loss of signal strength, necessitating the use of higher concentrations of primary and secondary antibodies to generate sufficient co-staining signal intensity ( Table 2 ).
1. Incubate each slide with 200 µL of distilled water with DNase (1 µL DNase/mL) for 2 minutes in a humidified incubation chamber at room temperature. 1a. NOTE-Incubation with DNase at this step is essential for high quality staining. DNases are highly unstable and can lose activity during routine handling if tubes are dropped or otherwise mishandled. Insufficient DNase digestion is a major cause of BrDU staining inconsistencies. It is therefore crucial to purchase certified quality DNase enzyme and to test each batch of DNase to confirm enzyme activity. Batches must be handled with extreme care and must be stored in small aliquots to prevent loss of activity due to repeated handling. 1b. NOTE-Optimal DNase incubation times must be empirically determined for each embryonic time-point. 2. Rinse the slides with BrdU wash solution (from kit 1:10 in distilled water) using a pipette. 3. Incubate with anti-BrdU antibody (1:10) in incubation buffer (from kit) for 45 minutes at room temperature. 4. Rinse with BrdU wash solution (from kit, 1:10 in distilled water) using a pipette. 5. Incubate slides with the secondary anti-mouse (1:10) antibody (from kit, diluted in the incubation buffer) for 45 minutes at room temperature. 6. Rinse the slides with 0.1% Tween 20 in 1X PBS using a pipette. 7. Incubate with Six2 and E-cad primary antibodies (both 1:200) in incubation buffer (3% donkey serum, 3% BSA, 0.1% Tween 20 in 1X PBS) overnight at 4°C. 
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Note. PCNA = proliferating cell nuclear antigen. BrdU = 5-bromo-2'-deoxyuridine; EdU = 5-ethynyl-2'-deoxyuridine. a These working dilutions were adjusted to be twice as concentrated for staining with BrdU (see "Labeling with BrdU" section).
8. Rinse with 0.1% Tween 20 in 1X PBS using a pipette. 9. Incubate with anti-rabbit (1:50) and anti-rat (1:100) secondary antibodies diluted in 1X PBS with 0.1% Tween 20 at room temperature for 45 minutes. 10. Rinse slides with 1X PBS using a pipette. 11. Mount slides with a coverslip and mounting media.
Label with PCNA 1. Incubate with Six2, E-cad (both 1:400) and PCNA (1:500) primary antibodies in incubation buffer (3% donkey serum, 3% BSA, 0.1% Tween 20 in 1X PBS) overnight at 4°C. 
Image Acquisition and Counting
Images are acquired at 40× magnification using a standard fluorescence or confocal microscope. The appropriate filter sets must be used to assure quality data. Here we have used a Zeiss AxioImager.A1 microscope with an AxioCamMRc digital camera, AxioVision Software, and Zeiss filter sets 20, 38, and 49. Digital images are manually counted using the free ImageJ Cell Counter Plugin or a similar image processing program. Importantly, digital cell counts may be reviewed for calibration purposes, to evaluate precision and/or possible counting bias. Automated or semi-automated cell counting programs are also available for purchase, but have additional hardware, software, and setup requirements, making them cost-prohibitive to smaller laboratories.
Image processing
1. For tissues older than embryonic day (E)13.5, multiple overlapping images can be taken and stitched together using Fiji/ImageJ software 47 
Data Analysis
The ratio of cells labeled by the proliferation marker to total number of nephron progenitor cells (marker/NPC) or of ureteric bud cells (marker/UB) was calculated for each section. Mean values were calculated for each kidney and compared between groups by t test. Data are presented as mean ± standard deviation.
Results and Discussion
Assessment of nephron progenitor cell proliferation is a critical parameter of kidney development in vivo. Here we have presented co-immunostaining protocols that we have optimized for BrdU, EdU, or PCNA, along with Six2 and E-cadherin to quantitatively assess in situ nephron progenitor cell and ureteric bud cell proliferation in embryonic murine kidney sections. To compare the 3 methods in the same tissues, CD1 timed pregnant dams were injected with both BrdU and EdU at E14.5. Kidneys were collected from 5 embryos, processed, and sectioned. A minimum of 9 serial sagittal sections were taken near the midline of each kidney, where the first ureteric bifurcation could be seen, and 3 consecutive sections were stained for each method as described above. Digital images were captured, and the number of stained cells was quantified for each color channel. A nephron progenitor cell proliferation index was calculated as the ratio of Six2-positive, proliferation marker-positive cells to total number of Six2-positive cells. A ureteric bud cell proliferation index was likewise calculated as the ratio of E-cadherin-positive, proliferation marker-positive cells to total number of E-cadherinpositive cells.
The protocols outlined in the Methods section have each been optimized to yield unambiguous nuclear staining of cells for BrDU, EdU, or bound PCNA together with Six2 and E-cadherin co-staining of nephron progenitor and ureteric bud cells, respectively. Notwithstanding, each protocol has distinct advantages and disadvantages. BrdU staining has long been considered a gold standard marker for measuring cell proliferation, with an immense body of evidence supporting its use as such. This protocol in conjunction with Six2 and E-cadherin co-staining is the lengthiest and most technically challenging of the three to perform. Its most notable challenge relates to localized staining inconsistencies, namely, staining of some tissue sections and absence of staining of other tissue sections on the same slide. Staining inconsistencies are resolvable by increasing DNase concentrations (at the expense of tissue morphology), suggesting that the absence of staining may be due at least in part to localized failures in DNase-dependent antigen exposure in these tissue sections. In contrast, while there is a smaller body of literature supporting the use of bound PCNA or EdU as markers of cell proliferation, neither of these protocols suffer from the same staining inconsistencies as BrDU staining, and both are far simpler technically to perform. However, the added necessity of distinguishing the punctate PCNA staining pattern of S phase cells from non-S phase cells ( Figure 6A ) in the bound PCNA protocol substantially increases the amount time needed to quantitate cell proliferation using the bound PCNA method. (Figure 6A ). In this context, the EdU protocol, though by virtue of being the most recent of the three to be introduced and thus having the smallest body of literature to lend itself-is both the most straightforward and rapid to perform. Another important caveat to recall is that of the 3 methods, the bound PCNA protocol alone can be performed retrospectively on fixed tissue as it does not require injection into the live animal.
Similar indices of cell proliferation are detected using BrdU and EdU; however, data precision is higher with the BrdU protocol, as evidenced by lower relative standard deviation in this method compared with EdU ( Figure 6B vs C) . Interestingly, PCNA staining yields a significantly lower nephron progenitor cell proliferation index compared with BrdU. Whereas BrdU and EdU mark a larger population of cells including those in both S phase and G 2 phase, bound PCNA labels only S phase cells at the time of fixation, which may explain in part the lower proliferation index associated with this method.
In summary, we present this methods article to the nephrology community in the hopes of providing a useful and cost-effective resource to quantitatively assess in situ cell proliferation of multiple cell lineages during kidney development in vivo. Each of the 3 methods optimized and described above present distinct advantages and disadvantages, which must be considered within the specific scientific context of a given experiment (Table 3) .
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